NRXP NRx Pharmaceuticals Inc. Total Asset Value of Company

NRXP (NRx Pharma) - company brandmark

The price action of NRx Pharmaceuticals (NRXP) total assets on the GURU.Markets platform is 19.50. NRx Pharmaceuticals is implementing AI receptor modeling to accelerate the development of neuropreparations while minimizing manual labor. Financial stability remains limited by the antidepressant testing phase, resulting in unstable inflows. Meanwhile, the focus on treating suicidal states provides access to highly sought-after and untapped market niches.

NRXP (NRx Pharmaceuticals) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company NRx Pharma (NRXP)

- current price and projected stock value:
Quote Chart nrxpharma.com|NRXP - Price Target Chart
- market capitalization data:
Market Valuation NRx Pharmaceuticals, Inc|NRXP - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share NRx Pharmaceuticals|NRXP - Book Capitalization|Market Capitalization to Book Value Ratio nrxpharma.com|NRXP - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio NRx Pharmaceuticals|NRXP - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio NRx Pharmaceuticals, Inc|NRXP - Company Aggregate Debts|Debts to Book Capitalization NRx Pharmaceuticals, Inc|NRXP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings NRx Pharmaceuticals|Critical Liquidity Ratio nrxpharma.com
- net income and valuation multiples indicators:
NRXP - Company Net Income
Fundamental valuation:NRx Pharmaceuticals
Manufactured products of NRx Pharmaceuticals

This indicator, calculated inversely via ROA, allows for the separation of real capital from market volatility by assessing the total resources under management control. An analysis of the organization's asset size confirms the financial base of NRx Pharmaceuticals (NRXP), providing the necessary stability for the long-term conduct of clinical trials for PTSD and depression drugs, which reinforces the company's fundamental image.

Key competitors

Total Asset Value of Company ALKS (alkermes.com)|Aggregate Company Assets Avadel Pharmaceuticals plc|atai Life Sciences NV - Total Asset Value of Company|Company Total Assets GHRS|MNMD (Mind Medicine Corp) - Aggregate Asset Value|Company Total Assets CMPS (COMPASS Pathways plc)|Company Total Assets lbpharma.us LBRX|DRUG - Aggregate Company Assets|Aggregate Asset Value VNDA (Vanda Pharma)|cybin.com (CYBN) - Aggregate Company Assets|Cumulative Company Assets Alto Neuroscience Corp|CING (Cingulate Inc) - Company Total Assets|Company Total Assets Silo Pharma Inc.|Cumulative Company Assets CPHI (China Pharma Holdings)|CMND (clearmindmedicine.com) - Aggregate Asset Value|Aggregate Company Assets Psyence Biomedical Limited PBM|SPRC (SciSparc Corp) - Total Asset Value of Company|SEEL - Aggregate Company Assets|Company Total Asset Base Virpax Pharmaceuticals VRPX|KRTX (Karuna Therapeutics, Inc.) - Cumulative Company Assets